Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Novo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

SEATTLE -- Weight loss drugs have gained momentum as treatment for obstructive sleep apnea (OSA) at sleep clinics across the ...

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...

Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren't as impressive as those promised ...

People who take weight-loss drugs hoping to achieve the impressive results observed in large clinical trials may need to ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

WEDNESDAY, June 11, 2025 (HealthDay News) — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and ...

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...